Abstract
During the last two decades since the first oncogene product called v-Src was identified as a constitutively activated mutant of a normal mitogenic gene (proto-oncogene) encoding a Tyr kinase called c-Src in early 1980s, it was firmly established that the malignant transformation of normal cells is caused by a combination of the following genetic events: overexpression of a protooncogene or constitutive activation of its gene product (mitogenic signal transducer), and deletion of a tumor-suppressor gene (also called anti-oncogene or anti-mitogenic gene) or dysfunction of its gene product (anti-mitogenic signal transducer).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bos, J. L. (1989) Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689.
Downward, J. (1998) Oncogenic RAS signaling network, in G Proteins, Cytoskel-eton and Cancer (Maruta, H. and Kohama, K., eds.), Landes Bioscience, Austin, TX, pp. 171–183.
Qiu, R., Che, J., Kirn, D., McCormick, F., and Symons, M. (1995) An essential role for Rac in RAS transformation. Nature 374, 457–459.
Qiu, R., Abo, A., McCormick, F., and Symons, M. (1997) CDC42 regulates anchorage-independent growth and is necessary for RAS transformation. Mol. CellBiol. 17, 3449–3458.
Lilienthal, J., Moon, S. Y., Lesche, R., Mammillapalli, R., Li, D., et al (2000) Genetic deletion of the PTEN tumor suppressor gene promotes cell motility by activation of Rac and CDC42 GTPases. Curr. Biol. 10, 401–404.
Nur-E-Kamal, M. S. A., Kamal, J., Quresh, M., and Maruta, H. (1999) The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-RAS-induced transformation. Oncogene 18, 7787–7793.
Manser, E., Leung, T., Salihuddin, H., Tan, L, and Lim, L. (1993) A nonreceptor Tyr kinase that inhibits the GTPase activity of CDC42. Nature 363, 364–367.
Manser, E., Leung, T., Salihuddin, H., Zhao, Z., and Lim, L. (1994) A brain Ser/Thr kinase activated by CDC42 and Rac. Nature 367, 40–46.
Symons, M., Derry, J., Karlak, B., Jiang, S., Lemahieu, V., and McCormick, F. (1996) Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42, is implicated in actin polymerization. Cell 84, 723–734.
Miki, H., Sasaki, T., Takai, Y., and Takenawa, T. (1998) Induction of filopodium formation by a WASP-related actin depolymerizing protein N-WASP. Nature 391, 93–96.
Van Aelst, L., Joneson, T., and Bar-Sagi, D. (1996) Identification of a novel Rac-interacting protein involved in membrane ruffling. EMBO J. 15, 3778–3786.
Kobayashi, K., Kuroda, S., Fukata, M., Nakamura T., Nagase, T., et al. (1998) P140Sra-1 (specifically Rac-associated protein) is a novel specific target for Rac GTPase. J. Biol. Chem. 273, 291–295.
Daniels, R., Zenke, F., and Bokoch, G. (1999) PIX stimulates PAK kinase activity through exchange factor-dependent and independent mechanisms. J. Biol. Chem. 274, 6047–6050.
Manser, E., Loo, T., Koh, C., Zhao, Z., Chen, X., et al. (1998) PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. Mol. Cell 1, 183–192.
Obermeier, A., Ahmed, S., Manser, E., Yen, S., Hall, C., and Lim, L.(1998) PAK promotes morphological changes by actin upstream of Rac. EMBO J. 17, 4328–4339.
Maruta, H., He, H., Anjali, T., and Nur-E-Kamal, M. S. A. (1999) Cytoskeletal tumor suppressors that block oncogenic RAS signaling. Ann. NYAcad. Sci. 886, 48–57.
Derossi, D., Chassaing, G., and Prochiantz, A. (1998) Trojan peptides: the penetratin system for intracellular delivery. Trends CellBiol. 8, 84–87.
Joliot, A., Pernelle, C., Deagostini-Bazin, H., and Pronchiantz, A. (1991) Anten-napedia homeobox peptide regulates neural morphogenesis. Proc. Nat. Acad. Sci. USA 88, 1864–1868.
Derossi, D., Joliot, A., Chassaing, G., and Prochiantz, A. (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10,444–10,450.
Williams, E., Dunican, D., Green, P., Howell, F., and Derossi, D. (1997) Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb-2-binding peptide. J. Biol. Chem. 272, 22,349–22,354.
He, H., Hirokawa, Y., Levitzki, A., and Maruta, H. (2000) An anti-RAS cancer potential of PP1, an inhibitor specific for SRC family kinases: in vitro and in vivo studies. Cancer J. Sci. Am. 6, 243–248.
He, H., Hirokawa, Y., Manser, E., et al. (2001) Signal therapy of RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 7, 191–202.
Maruta, H., He, H., Tikoo, A., Vuong-Nheu, T., and Nur-E-Kamal, M. S. A. (1999) G proteins, phosphatidylinositides, actin-cytoskeleton in the control of cancer growth. Microsc. Res. Tech. 47, 61–66.
Glick, A., Sporn, M., and Yuspa, S. (1991) Altered regulation of TGFβ-1 and TGFα in primary keratinocytes and papillomas expressing v-Ha-RAS. Mol. Carcinog. 4, 210–219.
Higashiyama, S., Abraham, J., Miller, J., Fiddes, J., and Klagsbrun, M. (1991) A heparin-binding growth factor secreted by macrophage-like cells is related to EGF. Science 251, 936–939.
Normanno, N., Selvan, M., Qi, C., Saeki, T., Johnson, G., et al. (1994) Amphi-regulin as an autocrine growth factor for c-Ha-Ras /c-ErbB2-transformed human mammary epithelial cells. Proc. Nat. Acad. Sci. USA 91, 2790–2794.
Mincione, G., Bianco, C., Kannan, S., Colletta, G., Ciardiello, F., et al. (1996) Enhanced expression of heregulin in ErbB2 and c-Ha-RAS transformed mouse and human mammary epithelial cells. J. Cell Biochem. 60, 437–446.
Levitzki A. and Gazit A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782–1788.
Hanke, J., Gardner, J., Dow, R., Changelian, P., Brissette, W., et al. (1996) Discovery of a novel, potent, and Src family-selective Tyr kinase inhibitor. J. Biol. Chem. 271, 695–701.
Maruta, H., Holden, J., Sizeland, A., and D’Abaco, G. (1991) The residues of RAS and Rap proteins that determine their GAP activities. J. Biol. Chem. 266, 11,661–11,668.
Tang, Y., Yu, J., and Field, J. (1999) Signals from the RAS, Rac and Rho GTPases converge on the PAK kinase in Rat-1 fibroblasts. Mol. Cell Biol. 19, 1881–1891.
Tikoo, A., Shakri, R., Connolly, L., Hirokawa, Y., Shishido, T., et al. (2000) Treatment of RAS-induced cancers by the F-actin bundling drug MKT-077. Cancer J. 6, 162–168.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Humana Press Inc.
About this protocol
Cite this protocol
Maruta, H., He, H., Nheu, T. (2002). Interfering with Ras Signaling Using Membrane-Permeable Peptides or Drugs. In: Manser, E., Leung, T. (eds) GTPase Protocols. Methods in Molecular Biology™, vol 189. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-281-3:075
Download citation
DOI: https://doi.org/10.1385/1-59259-281-3:075
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-934-6
Online ISBN: 978-1-59259-281-4
eBook Packages: Springer Protocols